CompanyGraph
Shanghai Miracure Pharmaceuticals Co., Ltd.
688373 · SSE · China
micurxchina.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $22.4M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 0.01: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.57BCNY530.88M · vs all stocks (USD)
Revenue (TTM)
150.62MCNY22.40M · vs all stocks (USD)
Profit Margin
-133.74%Beta
0.3790xvs all stocks
52-Week Change
-28.89%vs all stocks
Market Capitalization
3.57BCNY530.88M · vs all stocks (USD)
Enterprise Value
3.66BCNY544.93M · vs all stocks (USD)
Price to Sales (TTM)
24.66xPrice to Book (MRQ)
20.43xEnterprise to Revenue
24.33xEnterprise to EBITDA
-18.04xGross Margin
85.60%Profit Margin
-133.74%Operating Margin
-46.63%Return on Assets (TTM)
-16.78%Return on Equity (TTM)
-71.14%Revenue (TTM)
150.62MCNY22.40M · vs all stocks (USD)
Revenue per Share (TTM)
0.2280CNYUpdated Aug 21, 2026Quarterly Revenue Growth
26.60%Gross Profit (TTM)
128.17MCNY19.06M · vs all stocks (USD)
EBITDA (TTM)
-203.12MCNY-30.21M · vs all stocks (USD)
Net Income (TTM)
-201.43MCNY-29.96M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
28.58%Operating Cash Flow (TTM)
-174.14MCNY-25.90M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-109.68MCNY-16.31M · vs all stocks (USD)
Payout Ratio
0.00%Revenue
141.77MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
21.53MCNYFY2025 · Dec 31, 2025Gross Profit
120.24MCNYFY2025 · Dec 31, 2025Operating Income
-244.30MCNY-36.33M · vs all stocks (USD)
Pre-tax Income
-245.57MCNYFY2025 · Dec 31, 2025Income Tax Expense
-3.95MCNYFY2025 · Dec 31, 2025Net Income
-241.61MCNYFY2025 · Dec 31, 2025EBIT
-232.67MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-223.93MCNYFY2025 · Dec 31, 2025Research & Development
213.93MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
86.41MCNYFY2025 · Dec 31, 2025Other Operating Expenses
538.15KCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.41MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
12.89MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
-241.61MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-235.98MCNYFY2025 · Dec 31, 2025Free Cash Flow
-236.52MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
294.94MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-241.61MCNYFY2025 · Dec 31, 2025Stock-based Compensation
14.47MCNYFY2025 · Dec 31, 2025Other Non-cash Items
15.74MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-27.26MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.68MCNYFY2025 · Dec 31, 2025Capital Expenditures
-545.30KCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.50BCNYFY2025 · Dec 31, 2025Sale of Investments
2.67BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
165.49MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
205.70MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-116.46MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-8.88MCNYFY2025 · Dec 31, 2025Other Financing Charges
-12.06MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
68.31MCNYFY2025 · Dec 31, 2025Shares Outstanding
655.61MSharesUpdated Aug 21, 2026Float Shares
422.47MSharesUpdated Aug 21, 2026% Held by Insiders
43.99%vs all stocks
% Held by Institutions
3.20%vs all stocks
Total Cash (MRQ)
420.86MCNY62.59M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.6410CNYUpdated Aug 21, 2026Total Debt (MRQ)
370.97MCNY55.17M · vs all stocks (USD)
Total Debt to Equity (MRQ)
2.04xCurrent Ratio (MRQ)
2.07xBook Value per Share (MRQ)
0.2770CNYUpdated Aug 21, 2026Total Assets
705.09MCNY104.85M · vs all stocks (USD)
Total Current Assets
622.46MCNYFY2025 · Dec 31, 2025Total Liabilities
499.55MCNYFY2025 · Dec 31, 2025Total Non-current Assets
82.63MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
275.17MCNYFY2025 · Dec 31, 2025Total Current Liabilities
224.38MCNYFY2025 · Dec 31, 2025Cash
316.02MCNYFY2025 · Dec 31, 2025Cash Equivalents
79.66KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
316.10MCNYFY2025 · Dec 31, 2025Other Short-term Investments
135.54MCNYFY2025 · Dec 31, 2025Accounts Receivable
37.96MCNYFY2025 · Dec 31, 2025Inventory
50.25MCNYFY2025 · Dec 31, 2025Accounts Payable
80.30MCNYFY2025 · Dec 31, 2025Short-term Debt
106.21MCNYFY2025 · Dec 31, 2025Other Current Liabilities
28.30KCNYFY2025 · Dec 31, 2025Long-term Debt
273.42MCNYFY2025 · Dec 31, 2025Common Stock (Book)
656.23MCNYFY2025 · Dec 31, 2025Retained Earnings
-2.05BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
205.54MCNY30.57M · vs all stocks (USD)
52-Week Low
4.09CNYUpdated Aug 21, 202652-Week High
10.31CNYUpdated Aug 21, 202652-Week Change
-28.89%vs all stocks
Beta
0.3790xvs all stocks
50-Day MA
4.86CNYUpdated Aug 21, 2026200-Day MA
5.78CNYUpdated Aug 21, 2026Avg 10-Day Volume
18.10MSharesUpdated Aug 21, 2026Avg 30-Day Volume
18.34MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.3400CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.86Profit Margin: -1.34
Significant cash reserves alongside high leverageNotable
Cash (USD): 62,586,733.027Total Debt (USD): 55,166,732.178Debt-to-Equity: 2.04
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.07Altman Z-Score: 0.01
Financial Health
Altman Z-Score 0.01: distress zoneCritical
Altman Z-Score: 0.01
High structural barrier to entryNotable
Barrier to Entry: 16.80
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $22.4M, lower than 95% of all stocks globallySignificant
Revenue (USD): 22,398,017.324Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Assembly Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule
Contineum Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Jiangsu Bioperfectus Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Shanghai General Healthy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wuhan Easydiagnosis Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hinova Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Lifestrong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule